CRVS vs. PAHC, ARDX, COLL, NTLA, RCUS, AVDL, SYRE, PHVS, CRMD, and NAGE
Should you be buying Corvus Pharmaceuticals stock or one of its competitors? The main competitors of Corvus Pharmaceuticals include Phibro Animal Health (PAHC), Ardelyx (ARDX), Collegium Pharmaceutical (COLL), Intellia Therapeutics (NTLA), Arcus Biosciences (RCUS), Avadel Pharmaceuticals (AVDL), Spyre Therapeutics (SYRE), Pharvaris (PHVS), CorMedix (CRMD), and Niagen Bioscience (NAGE). These companies are all part of the "pharmaceutical products" industry.
Corvus Pharmaceuticals vs.
Phibro Animal Health (NASDAQ:PAHC) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, community ranking, media sentiment and dividends.
Phibro Animal Health has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 0.67, indicating that its stock price is 33% less volatile than the S&P 500.
99.3% of Phibro Animal Health shares are held by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are held by institutional investors. 50.1% of Phibro Animal Health shares are held by company insiders. Comparatively, 28.5% of Corvus Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Phibro Animal Health received 22 more outperform votes than Corvus Pharmaceuticals when rated by MarketBeat users. However, 61.97% of users gave Corvus Pharmaceuticals an outperform vote while only 59.81% of users gave Phibro Animal Health an outperform vote.
Phibro Animal Health has a net margin of 1.75% compared to Corvus Pharmaceuticals' net margin of 0.00%. Phibro Animal Health's return on equity of 25.35% beat Corvus Pharmaceuticals' return on equity.
In the previous week, Phibro Animal Health had 1 more articles in the media than Corvus Pharmaceuticals. MarketBeat recorded 7 mentions for Phibro Animal Health and 6 mentions for Corvus Pharmaceuticals. Phibro Animal Health's average media sentiment score of 1.57 beat Corvus Pharmaceuticals' score of 0.92 indicating that Phibro Animal Health is being referred to more favorably in the media.
Phibro Animal Health presently has a consensus price target of $20.00, suggesting a potential downside of 13.98%. Corvus Pharmaceuticals has a consensus price target of $15.00, suggesting a potential upside of 313.22%. Given Corvus Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Corvus Pharmaceuticals is more favorable than Phibro Animal Health.
Phibro Animal Health has higher revenue and earnings than Corvus Pharmaceuticals. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.
Summary
Phibro Animal Health beats Corvus Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Corvus Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CRVS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Corvus Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:CRVS) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy CRVS Stock Free CRVS Stock Alerts